Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

US
UK
ES
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

US
UK
ES
Find a centre
Find a doctor

Cancer

Cancer
2021-06-10T00:00:00.000+08:00
Ongoing

KEYNOTE-992

KEYNOTE-992
Bladder cancer

Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).

Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).

Trial overview

Topic

Bladder cancer

Description

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC).

Eligibility criteria
  • Muscle Invasive bladder cancer
  • Not planned for surgery
Study details

The treatment involves immunotherapy plus chemotherapy plus radiotherapy vs the standard of care, chemotherapy with radiotherapy. While on treatment there will be regular blood tests, urine tests, cystoscopies, and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore

North Shore :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.